AsianScientist (Apr. 8, 2013) – Life science provider New England Biolabs (NEB) has extended its global subsidiary network with the opening of New England Biolabs Pte. Ltd. in Singapore.
The Ipswich, Massachusetts-based NEB, which has a large share of the global restriction enzyme market, is a privately held company and currently maintains subsidiary offices in Canada, China, France, Germany, Japan, and the United Kingdom.
“The Singapore facility will provide the vibrant local scientific research community with more efficient access to the latest NEB products, technical support in the local time zone and languages, as well as OEM partnership opportunities,” says Sue Yap, General Manager for the Singapore office.
Singapore, recently cited by Scientific American as the world’s third most innovative country in biotech, is home to more than 5,000 life science researchers, numerous start-ups, and pharmaceutical companies.
Its significance to the biological sciences was reflected this past January, when the country hosted the inaugural Global Young Scientists Summit (GYSS@one-north), featuring 12 Nobel Prize Laureates. Among these was the Chief Scientific Officer of NEB, Sir Richard Roberts, who conducted a seminar to inaugurate the opening of the NEB office.
“Singapore has a world class reputation in the life sciences. This new office will allow us to offer even greater personalized service and, when appropriate, to explore higher levels of collaboration, especially with the startup biotech companies now multiplying in Singapore,” said Sir Roberts.
——
Source: NEB; Photo: jeckman/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
